Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer, primarily through its proprietary CyPath® Lung test, and operates a clinical pathology laboratory (Precision Pathology Laboratory Services, LLC). It is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenue | $1,853,597 | $2,406,391 |
| Net Loss | $(2,660,417) | $(1,961,815) |
| Loss Per Share (Basic & Diluted) | $(0.16) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $444,706 | $2,453,165 |
| Accumulated Deficit | $(56,304,727) | $(46,566,294) |
| Working Capital | $(1,551,627) | $(409,807) |
| Total Liabilities | $4,107,879 | $3,911,631 |
Note: Working Capital calculated as Total Current Assets ($1,863,782) minus Total Current Liabilities ($3,415,409).
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by approximately 23% ($552,794) compared to Q1 2024. This was a strategic decision to discontinue unprofitable pathology services to focus on high-margin CyPath® Lung testing.
- CyPath® Lung Growth: Despite the overall revenue drop, revenue specifically from CyPath® Lung testing increased by approximately 275% (from $45,000 to $169,000) due to a 200% increase in test results delivered.
- Expense Fluctuations:
- Direct Costs: Decreased 13% ($205,581) due to operational streamlining and labor cost reductions.
- Clinical Development: Increased 183% ($89,393) driven by professional fees for managing the pivotal clinical trial strategy.
- Selling, General & Administrative (SG&A): Increased 12% ($266,605) due to added personnel to support sales growth.
- Cash Position: Cash and cash equivalents declined by $660,585 during the quarter, resulting in a net cash burn of $1.64 million from operating activities.
Guidance, Outlook, Risks, and Unusual Items
Going Concern and Liquidity
Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance of the financial statements. As of March 31, 2025, cash on hand was $0.4 million. Management anticipates current resources will support operations only through August 2025 without additional funding.
Recent Financing and Subsequent Events
- February 2025 Warrant Inducement: The Company raised approximately $1.4 million through the exercise of 2.44 million warrants at a reduced price of $0.58 per share.
- May 2025 Public Offering: Subsequent to the period end, on May 7, 2025, the Company completed a public offering raising $3.25 million in gross proceeds. This included 10.16 million shares (including pre-funded warrants) and accompanying warrants.
Key Risks
- Nasdaq Compliance: The Company received notice of non-compliance with the Nasdaq Minimum Bid Price Requirement ($1.00) and Stockholders' Equity requirement ($2.5 million; current equity is ~$1.4 million). Failure to regain compliance by August 6, 2025, could result in delisting.
- Capital Needs: Continued operations depend on raising additional capital through equity, debt, or strategic partnerships. Failure to secure funding could force curtailment of operations.
- Regulatory Approval: The Company is seeking FDA de novo classification for CyPath® Lung and CE-marking in the EU; success is not guaranteed.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.25 million raised in May 2025 to extend operations beyond the projected August 2025 runway.
- Nasdaq Status: Monitor the Company's progress in meeting the $1.00 minimum bid price and $2.5 million stockholders' equity requirements to avoid delisting.
- Revenue Mix: Assess the sustainability of the shift away from general pathology services toward CyPath® Lung testing and the associated reimbursement rates (price increased to $2,900 in April 2025).
- Dilution Impact: Review the impact of the May 2025 offering and outstanding warrants (12.87 million as of March 31, 2025) on existing shareholder equity.
- Clinical Trial Progress: Confirm the status and cost trajectory of the pivotal clinical trial, which drove a significant increase in clinical development expenses.